Altered expression of thioredoxin reductase-1 in dysplastic bile ducts and cholangiocarcinoma in a hamster model.
- Author:
Byung IL YOON
1
;
Dae Yong KIM
;
Ja June JANG
;
Jeong Hee HAN
Author Information
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords: cholangiocarcinoma; dysplastic bile duct; hamster; thioredoxin reductase-1
- MeSH: Animals; Bile Duct Neoplasms/*enzymology/pathology; Bile Ducts/enzymology/pathology; Cholangiocarcinoma/*enzymology/pathology; Cricetinae; Disease Models, Animal; Immunohistochemistry; Mesocricetus; Precancerous Conditions/*enzymology/pathology; Thioredoxin Reductase (NADPH)/*biosynthesis
- From:Journal of Veterinary Science 2006;7(3):211-216
- CountryRepublic of Korea
- Language:English
- Abstract: Thioredoxin reductase 1 (TrxR) is a homodimeric selenoenzyme catalyzing thioredoxin (Trx) in an NADPHdependent manner. With regard to carcinogenesis, these redox proteins have been implicated in cell proliferation, transformation and anti-apoptosis. In the present study, using a hamster cholangiocarcinoma (ChC) model, we evaluated the immunohistochemical expression pattern of TrxR in precancerous lesions and ChCs as well as in normal bile ducts. The goal of this study was to determine the potential role and importance of TrxR in cholangiocarcinogenesis. For the ChC model, we obtained liver tissue specimens with dysplastic bile ducts prior to the development of ChC 8 weeks after initiation of the experiment and ChC samples at 27 weeks. The immunohistochemical analysis showed diffuse cytoplasmic overexpression of TrxR in the dysplastic bile duct epithelial cells as well as in cholangiocarcinoma; this was comparable to the negative or weakly positive in normal and type 1 hyperplastic bile ducts. However, TrxR appeared to be considerably down-regulated in the ChCs when compared to the higher expression observed in the dysplastic bile ducts. Therefore, these results suggest that TrxR overexpression followed by down-regulation might be an important event in cholangiocarcinogenesis, especially at early stages including the cellular transformation of candidate bile ducts. Further studies are however required to determine whether TrxR may be a potential target molecule for chemoprevention against cholangiocarcinogenesis. In addition, the molecular mechanism as well as the importance of the loss of TrxR in the development of cholangiocarcinoma, following dysplastic transformation of bile duct cells, also remains to be clarified.
